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ABSTRACT
Objective: To report the frequency and type of antibodies against neuronal surface antigens
(NSA-ab) in limbic encephalitis (LE).
Methods: Analysis of clinical features, neuropathologic findings, and detection of NSA-ab using
immunochemistry on rat tissue and neuronal cultures in a series of 45 patients with paraneoplas-
tic (23) or idiopathic (22) LE.
Results: NSA-ab were identified in 29 patients (64%; 12 paraneoplastic, 17 idiopathic). Thirteen
patients had voltage-gated potassium channels (VGKC)-ab, 11 novel NSA (nNSA)-ab, and 5
NMDA receptor (NMDAR)-ab. nNSA-ab did not identify a common antigen and were more fre-
quent in paraneoplastic than idiopathic LE (39% vs 9%; p  0.03). When compared with
VGKC-ab or NMDAR-ab, the nNSA associated more frequently with intraneuronal antibodies
(11% vs 73%; p  0.001). Of 12 patients (9 nNSA-ab, 2 VGKC-ab, 1 NMDAR-ab) with paraneo-
plastic LE and NSA-ab, concomitant intraneuronal antibodies occurred in 9 (75%). None of these
12 patients improved with immunotherapy. The autopsy of three of them showed neuronal loss,
microgliosis, and cytotoxic T cell infiltrates in the hippocampus and amygdala. These findings
were compatible with a T-cell mediated neuronal damage. In contrast, 13 of 17 (76%) patients
with idiopathic LE and NSA-ab (8 VGKC-ab, 4 NMDAR-ab, 1 nNSA-ab) and 1 of 5 (20%) without
antibodies had clinical improvement (p  0.04).
Conclusions: In paraneoplastic limbic encephalitis (LE), novel antibodies against neuronal surface
antigens (nNSA-ab) occur frequently, coexist with antibodies against intracellular antigens, and
these cases are refractory to immunotherapy. In idiopathic LE, the likelihood of improvement is
significantly higher in patients with NSA-ab than in those without antibodies. Neurology® 2008;
71:930–936
GLOSSARY
GAD  glutamic acid decarboxylase; LE  limbic encephalitis; NMDAR  N-methyl-D-aspartate receptor; NSA  neuronal
surface antigens; nNSA  novel NSA; SCLC  small-cell lung cancer; VGKC  voltage-gated potassium channels; WBC 
white blood cells.
Limbic encephalitis (LE) was initially identified as a paraneoplastic neurologic syndrome char-
acterized by subacute onset of short-term memory loss, seizures, psychiatric changes, and neu-
roradiological or pathologic evidence of involvement of the amygdala and medial aspect of
temporal lobes.1 Paraneoplastic LE usually associates with onconeural antibodies that help to
confirm the diagnosis and guide in the search of the tumor.2 However, a significant proportion
of patients with paraneoplastic LE do not present onconeural antibodies.1
Recent studies using new techniques to detect neuronal antibodies against neuronal surface
antigens (NSA) identified serum antibodies against voltage-gated potassium channels (VGKC)
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antibodies (NMDAR-ab) in young women
with ovarian teratoma and an encephalitis
that involves neural structures beyond the
limbic system.4
In the present study, we analyzed the
presence of NSA antibodies (NSA-ab) using
neuronal cultures in a series of 45 patients
with paraneoplastic or idiopathic LE with the
aim to identify new clinical-immunologic as-
sociations.
METHODS
Patients. We review all patients with final diagnosis of LE
whose serum was sent to our laboratory (Barcelona, Spain) be-
tween 2000 and 2007 for analysis of antineuronal antibodies. LE
was defined by the subacute onset of short-term memory loss,
behavior change, seizures, and involvement of the temporal lobes
by EEG, imaging studies, or postmortem examination.2 LE was
considered definite paraneoplastic if a tumor was diagnosed or
the serum presented well characterized onconeural antibodies.2
The diagnosis of definite idiopathic LE required the absence of
cancer and well characterized onconeural antibodies, and a
follow-up of at least 3 years. LE patients with a shorter follow-up
were classified as possible idiopathic LE. The information was
obtained from forms filled out by the referring neurologists,
telephone interviews, and review of the clinical records. Nine-
teen (42%) patients were personally seen by at least one of the
authors.
Immunologic studies. Onconeural antibodies (Hu, Yo, Ri,
CV2, Ma2, amphiphysin, Tr, ZIC4, ANNA3, PCA2) were
screened by immunohistochemistry performed on frozen sec-
tions of paraformaldehyde-perfuse rat cerebellum using an
avidin-biotin immunoperoxidase technique and confirmed by
immunoblot when indicated.5
NSA-ab were identified by immunocytochemistry of rat hip-
pocampal neuronal cultures as previously described.4 Briefly, live
neurons grown on coverslips were incubated with the patients’
serum (dilution 1:400) or CSF (1:10) for 1 hour at 37°C,
washed, fixed with 4% paraformaldehyde, and immunoreacted
with anti-human IgG Alexa Fluor secondary antibody (Molecu-
lar Probes, Eugene, OR). Results were photographed under a
fluorescence microscope using Zeiss Axiovision software (Zeiss,
Thornwood, NY). To confirm the specificity of the neuronal
reactivity, all positive samples were preabsorbed with the non-
neuronal cell line HEK293 to remove antibodies that could react
with non-neuronal specific surface antigens.
Positive samples were further characterized by immunohisto-
chemistry on frozen sections of nonperfused rat brain fixed in
paraformaldehyde using an avidin-biotin immunoperoxidase
technique as described.6 This immunohistochemical assay is op-
timized to identify antibodies to cell surface antigens and readily
recognize VGKC and NMDAR antibodies.6 To determinate if
novel NSA (nNSA)-ab targeted similar epitopes, tissue sections
preincubated with patient’s serum positive for nNSA-ab were
subsequently incubated with biotinylated IgG isolated from the
serum of two other nNSA-ab-positive patients. Abrogation of
the reactivity indicated both nNSA-ab reacted with the same
epitopes.6
Positive samples for VGKC antibodies were further con-
firmed by radioimmunoassay3 and those for NMDAR antibodies
by immunocytochemistry on HEK293 cells transfected with
plasmids containing rodent NR1, NR2A, or NR2B subunits of
the NMDAR as described.4
Neuropathology. Paraffin sections of hippocampus and
amygdala from autopsy of four patients with NSA-ab were pro-
cessed for immunohistological techniques using a panel of anti-
bodies: glial fibrillar acidic protein (GFAP; Dako, Carpinteria,
CA; dilution 1:6,000) for astrocytes, CD68 (Novocastra Labora-
tories, Newcastle upon Tyne, UK; 1:3,000) for microglia, CD20
(Novocastra Laboratories; 1:800) for B-lymphocytes, CD3 (No-
vocastra Laboratories; 1:60) for T-lymphocytes, CD4 (Novocas-
tra Laboratories; 1:5) for helper T-cells, CD8 (Novocastra
Laboratories; 1:10) for suppressor/cytotoxic T-cells, T-cell re-
stricted intracellular antigen 1 (Tia-1; Immunotech, Marseille,
France; 1:100) for cytotoxic T-lymphocytes, and complement
component 9 (C9) (Novocastra Laboratories; 1:50) as de-
scribed.7 All sections were evaluated by two neuropathologists
blinded to the immunologic status of the patients.
RESULTS The series included 23 paraneoplastic
and 22 idiopathic LE (13 were definitive idiopathic
LE). NSA-ab were detected in 29 (64%) patients (17
with idiopathic LE). Thirteen patients had VGKC-
ab, 11 nNSA-ab, and 5 NMDAR-ab. All paraneo-
plastic LE patients presented some type of antibody.
Isolated NSA-ab were found in 3 patients, onconeu-
ral or other antibodies against intraneuronal antigens
in 11, and both antibody types in 9 (figure 1). By
contrast, 17 patients with idiopathic LE had NSA-
ab, 1 patient also had anti-glutamic acid decarboxyl-
ase (GAD) antibodies, 5 were seronegative (figure 1).
LE and novel NSA antibodies. nNSA-ab were more
frequent in paraneoplastic than in idiopathic LE (9/23
[39%] vs 2/22 [9%]; p  0.03) and had concomitant
intraneuronal antibodies more frequently than
VGKC-ab or NMDAR-ab (8/11 [73%] vs 2/18
[11%]; p  0.001) (figure 1). The clinical and immu-
nologic features of the 11 patients with nNSA-ab are
summarized in tables 1 and 2. The median age was 66
years (range: 44 to 81 years) and seven were men. Two
patients had definite idiopathic LE and nine paraneo-
plastic LE associated with small-cell lung cancer
(SCLC) in six. Four patients presented concomitant
onconeural antibodies (amphiphysin: 2, CV2,
Hu), and three antibodies against other intraneuronal
antigens: GAD, SOX1,8 and calmodulin-like kinase9
(figure 1). The clinical presentation was similar to
that of patients with other NSA-ab (tables e-1 and
e-2 on the Neurology® Web site at www.neurology.
org) or isolated onconeural antibodies (table e-3).
The frequency of hyponatremia (50%) at diagnosis
was lower but not significantly different from that
seen in idiopathic LE patients with VGKC-ab.3
By definition, all 11 sera with nNSA-ab reacted
with neurons in culture.
To ensure (figure 2) that the assay did not identify
antibodies against antigens located in the cytoplas-
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mic side of the membrane, neurons were immuno-
reacted with amphiphysin or GAD-ab-positive
serum from patients without LE and the experi-
ments were negative. The immunoreactivity on
paraformaldehyde-fixed rat sections of the 11 sera is
summarized in table 2. Six sera labeled with variable
intensity the neuropil of hippocampus, cerebellum,
and cerebral cortex (table 2, figure 2). None of the
sera blocked the reactivity in the neuropil of the
biotinylated IgG from a patient positive for
nNSA-ab (patient 4, table 2). However, two sera
blocked, completely (patient 4, table 2) or par-
tially (patient 6, table 2), the biotinylated IgG reac-
tivity of a previously reported patient with
treatment-responsive LE and thymic carcinoma (Pa-
tient 5, of reference 6).
LE and VGKC antibodies. Eleven of the 13 patients
with VGKC antibodies presented an idiopathic LE
(table e-1). The clinical features were in line with
previously reported series of VGKC antibody-
associated LE.10 The other two patients had a para-
neoplastic LE and both also had a concomitant
intraneuronal antibody against SOX1 and am-
phiphysin. The first patient, previously reported, was
a 47-year-old man with a steroid-responsive LE who
had a relapsing course associated with a SCLC.11 The
second patient was a 66-year-old woman with a LE
Figure 1 Distribution of limbic encephalitis according to etiology and serum antibody reactivity
NMDAR  NMDA receptor; NSA  neuronal surface antigens; VGKC  voltage-gated potassium channel.









1 77/M SCLC Memory impairment, behavior change Bilateral No No
2 72/M Bladder Memory impairment, behavior change Normal No Yes
3 70/M SCLC Seizures, memory impairment Normal† No Yes
4 44/F Thymoma Behavior change, confusion Not done† Yes (15 WBC) No
5 66/F Pancreas Behavior change, memory impairment Right No Yes
6 81/F SCLC Memory impairment Bilateral No Yes
7 69/M SCLC Seizures, memory impairment Left NA No
8 58/M SCLC Seizures, memory impairment Bilateral Yes (15 WBC) Yes
9 60/M SCLC Status epilepticus Left Yes‡ NA
10 45/M None§ Memory impairment Right No No
11 49/F None§ Memory impairment, seizures Bilateral No No
*Predominant symptom listed first.
†LE confirmed at autopsy.
‡Number of WBC unknown.
§Idiopathic LE.
SCLC  small-cell lung cancer; WBC  white blood cells; NA  not available.
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associated with amphiphysin and VGKC antibodies
who made a progressive course despite immuno-
suppressor therapy. Mammography showed a lesion
compatible with a breast cancer. Because of the
clinical situation, the family refused any further
studies. The neuropathologic study is described
below.
LE and NMDAR antibodies. Five patients had
NMDAR antibodies (table e-2). Three were women;
Table 2 Immunologic features and outcome of patients with limbic encephalitis (LE) and novel neuronal




Clinical response (survival in
months)Intraneuronal Neuropil Immunotherapy Chemotherapy
1 Amphiphysin Unknown* Steroids, IVIg No No response (dead, 1)
2 Amphiphysin Unknown* Steroids No No response (dead, 9)
3 GAD Hippocampus  cerebellum
 cortex
Steroids, IVIg No No response (dead, 3)
4 CV2 (CRMP5) Hippocampus  cerebellum
 cortex
No No No response (dead, 0.5)
5 Calmodulin-like
kinase†
Hippocampus None Yes No response (dead, 13)
6 SOX1 Hippocampus  cerebellum
 cortex
Steroids Yes No response (dead, 30)
7 Negative Hippocampus  cerebellum
 cortex
No Yes No response (dead, 2)
8 Hu Negative Steroids, IVIg Yes No response (dead, 21)
9 Negative Negative Steroids No No response (dead, 2)
10 Negative Negative Steroids No No response (alive,  46)
11 GAD Hippocampus  cerebellum
 cortex
No No Complete recovery (alive,  81)
*Amphiphysin reactivity prevented the identification of addition staining in the rat sections.
†Antigen identified by screening of a c-DNA library of fetal brain (unpublished).
Figure 2 Two sera with novel NSA antibodies as defined by the labeling of non-permeabilized rat
hippocampal neurons (A, C) presenting different immunoreactivity on sections of rat brain (B, D)
The first serum (A, B), which also had Hu antibodies as seen in the rat brain section, do not immunolabel the neuropil in
contrast to the robust reactivity with the neuropil of the hippocampus of the second serum (C, D). Bar  10 m (A), 180 m
(B), 20 m (C), 200 m (D).
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age range, 20 to 32 years. Two patients presented
with the classic syndrome associated with these anti-
bodies4 and one with isolated status epilepticus.
Two patients were men aged 53 and 76 years. The
first patient improved after steroid treatment and no
tumor has been found after a follow-up of 12
months.12 The second patient had a subacute onset
of memory loss and confusion that evolved to diffuse
encephalopathy, severe hyponatremia, and death in 2
weeks. Routine blood and CSF analysis and cranial
MRI were normal. EEG showed generalized slowing
without epileptic features. The autopsy study dem-
onstrated a SCLC with mediastinal and hepatic me-
tastasis. The neuropathologic study is described below.
Seronegative LE. Five patients with idiopathic LE
(definite in three) did not present any intraneuronal
or NSA-ab in the serum or CSF (three samples stud-
ied). The median age was 64 years (range: 40 to 67
years) and three were men. There was no previous
history of autoimmune disorders. Two patients had a
prodromic syndrome with fever and malaise. The LE
presented with an acute, in days, memory deficit and
confusion. None had seizures. CSF pleocytosis was
observed in three patients and hyponatremia in one.
Neuropathology. A postmortem study of the brain
was performed in four patients with NSA-ab. Three
of them, with nNSA-ab (patients 1 and 4 of table 1)
or VGKC-ab (patient 12 of table e-1), had a con-
comitant onconeural antibody. The fourth patient
presented isolated NMDAR-ab and SCLC (patient 5
of table e-2). Death occurred less than 2 months
since the onset of the LE in three patients and two
patients did not receive any immunotherapy. The
hippocampus and amygdala of the four patients ex-
hibited variable grades of neuronal loss, astrogliosis,
microglial hyperplasia and activation, and inflamma-
tory infiltrates of B (mainly perivascular) and T cells
(perivascular and parenchymal). The hippocampus
of the patient with isolated NMDAR-ab showed less
severe neuronal loss and gliosis compared with the
other three patients. Tia-1-immunoreactive T-cells
were present in the samples of the three patients with
concomitant onconeural and NSA-ab but not in the
hippocampus of the patient with NMDAR-ab (figure
3). Complement deposits were not observed in the
brain tissue of the four patients.
Treatment and outcome. The clinical outcome is
summarized in table 2 and tables e-1 to e-3. A clini-
cal response, defined by complete recovery of the
neurologic deficits or mild residual memory that did
not interfere with normal daily activities, was ob-
served in 13 (76%) of 17 patients with NSA-ab but
Figure 3 Photomicrographs of the hippocampus of the patient with isolated NMDAR-ab (A, B) and the
patient with amhiphysin and nNSA-ab (C, D)
There is mild neuronal loss in the pyramidal layer of the first patient (A), in contrast with the severe loss observed in the
hippocampus of the patient with amhiphysin and nNSA-ab (C). Both hippocampi presented perivascular and parenchima-
tous infiltrates of CD3  cells (T-cells) (B, D). However, Tia-1  cells (cytotoxic T-cells) in close apposition with neurons were
only observed in the hippocampus of the patient with amhiphysin and nNSA-ab (D, insert). Bar  100 m (A and C), 15 m (B,
D, and insert).
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in only 1 (20%) of the 5 seronegative patients (p 
0.04) with idiopathic LE (figure 1). All 22 patients
are alive, one lost, after a median follow-up of 40
months (range 7 to 120 months). By contrast, none
of the 12 patients with NSA-ab, nine of them with
additional intraneuronal antibodies, and paraneo-
plastic LE responded to treatment and all died with a
median survival of 6 months (range 0.5 to 30
months). This poor outcome was similar to that of
six LE patients with isolated Hu or amphiphysin-ab
(figure 1, table e-3).
DISCUSSION This study identified NSA-ab in
64% of patients with LE. The combined results of
immunocytochemistry on cultures of rat hippocam-
pal neurons,6 and the standard detection of antibod-
ies against intraneuronal antigens,2 demonstrated
antibodies with a potential pathogenic role or mark-
ers of the underlying cancer in 89% of the patients.
Only 5 (11%) patients, all with idiopathic LE, were
antibody negative.
nNSA-ab were more frequently detected in pa-
tients with paraneoplastic LE, usually associated with
SCLC, and the majority of them also presented anti-
bodies against intraneuronal antigens. The immuno-
chemical studies and competitive inhibition assays
suggest that nNSA-ab are heterogeneous and prob-
ably target different membrane antigens. How-
ever, the two sera that completely blocked the
neuropil immunoreactivity of each other pre-
sented a thymic tumor suggesting that LE associ-
ated with thymic neoplasms may be associated
with a common nNSA-ab.6
Although LE with NSA-ab usually have a good
prognosis,13 our study shows that the outcome of
paraneoplastic LE with nNSA-ab is poor. Several rea-
sons could account for this evolution. Only four of
the nine patients received tumor therapy, which is
critical to improve the paraneoplastic syndrome.14
Four patients had an associated onconeural antibody
and the autopsy in three of them disclosed pathologic
features compatible with a T-cell driven immune re-
sponse that could be the cause of irreversible defi-
cits.15 The lack of improvement of the other five
patients (one was not treated) is less clear. In ab-
sence of pathologic studies, we can only speculate
that the immune response included a T-cell response
or that the antibodies caused an irreversible neuronal
damage as suggested in two patients with encephalitis
and NMDAR-ab.4
Although VGKC-ab often associates with idio-
pathic LE,16 our study confirms that these patients
may have a tumor, usually thymoma17 or SCLC.11
Our two patients with paraneoplastic LE and
VGKC-ab also had intraneuronal antibodies,
SOX1-ab (previously called anti-glial nuclear anti-
body or AGNA),18 and amphiphysin-ab. In a previ-
ous study, VGKC-ab were identified in 3 (5%) of 63
patients with paraneoplastic neurologic syndromes
and amphiphysin-ab. Two of them had LE and an
encephalopathy that was not further characterized.19
We found NSA-ab in three of the four patients with
paraneoplastic LE and amphiphysin-ab compared to
one of 10 patients with other onconeuronal antibod-
ies. Although the numbers are small, future studies
will be important to confirm this association that
may have clinical and research implications. For ex-
ample, passive transfer experiments using IgG from
sera positive for amphiphysin-ab could show discor-
dant results depending on the presence or absence of
concomitant NSA-ab.20
Antibodies to NMDAR were initially reported in
young women with encephalitis and ovarian teratoma.4
The current series emphasizes several known charac-
teristics of the disorder, such as the frequent response
to treatment and possible occurrence without tumor
association.2 A novel finding is the association with
SCLC in one patient, a unique feature among 99
patients with anti-NMDAR encephalitis (Dalmau,
data not published).
Five patients with idiopathic LE were seronega-
tive. The acute onset of symptoms and the presence
of CSF pleocytosis in three patients suggest the disor-
der could be immune mediated. None of the patients
presented with seizures, which may cause hippocam-
pal edema and MRI T2 abnormalities identical to
those caused by the inflammatory process associated
with LE.21 Previous work demonstrated that defini-
tive LE may present with acute onset of seizures or
status epilepticus.22 However, it can be impossible to
diagnose autoimmune LE vs other disorders in pa-
tients presenting with seizures and the indicated
MRI changes unless there is evidence of a systemic
tumor, presence of onconeural antibodies, or dem-
onstration of inflammatory infiltrates in the brain
biopsy.22 Without these clues, the diagnosis of idio-
pathic, antibody-negative LE is uncertain, particu-
larly when the MRI changes occur late in the
evolution of the disorder.23
Data from this series and previous studies per-
formed in a center with different referral patterns13
highlight the frequency (89% and 92%) of immune
responses in patients with LE defined by rigorous
clinical criteria. These findings should be considered
when making clinical decisions. For example, the ab-
sence of onconeuronal or VGKC antibodies does not
necessarily imply that the disorder is not immune
mediated or will not respond to immunotherapy.23
Sera and CSF of these patients should be further
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studied in research centers, and immunotherapy
should be considered.
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